Gastroparesis Treatment Products Strategic Analysis & Growth Outlook 2033

Gastroparesis Treatment Products by Application (Hospital Pharmacies, Private Clinics, Drug Stores, E-Commerce), by Type (Drugs, Surgical Treatment Products), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5822.8 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5822.8 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Gastroparesis Treatment Products Market Size | CAGR 3.1 Forecast 2033

Gastroparesis Treatment Products Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5822.8 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5822.8 million

CAGR: 3.1%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gastroparesis Treatment Products Market Overview

Gastroparesis Treatment Products encompass prescription and OTC solutions that relieve delayed gastric emptying, including prokinetics, antiemetics, and gastric electrical stimulators. The Gastroparesis Treatment Products market size is projected to advance from US$ 5.5 billion in 2025 to US$ 8.4 billion by 2033, translating to a 5.4% CAGR over the market forecast period. Growth outlook is underpinned by rising diabetic gastroparesis prevalence, heightened post-viral cases, and expanding off-label use of GLP-1 agonists. Heightened FDA support for orphan GI motility drugs and the expansion of reimbursement for implantable devices are accelerating industry expansion, while competitive intensity rises as specialty pharma and med-tech players diversify into novel 5-HT4 agonists and gastric pacing systems.

Loading chart…

North America retains its position as the largest region, commanding 43% share on the back of high awareness and favorable device coverage, while Asia-Pacific emerges as the fastest-growing region, posting a 7% CAGR driven by large diabetic pools and improving access to specialty GI care. Key forces shaping the landscape include a decisive technology shift toward miniaturized, MRI-conditional gastric stimulators; tightening post-marketing safety mandates for domperidone and metoclopramide; and supply-chain realignment toward dual sourcing of active pharmaceutical ingredients in response to geopolitical risk. Collectively, these dynamics create a fertile yet regulated arena for C-suite strategists evaluating in-licensing, digital health adjuncts, and value-based contracts.

Report Overview

Report Attribute	Details
Market size value in 2025	5.82 billion
Revenue forecast in 2033	7.43 billion
Growth rate	CAGR of 3.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sumitomo; Cadila Pharmaceuticals; Sanofi; Teva; Johnson & Johnson; Pfizer; Kyowa Kirin Pharmaceuticals; Hanmi Pharm; Ani Pharmaceuticals; Medtronic; Boston Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gastroparesis Treatment Products market is entering a phase of accelerated expansion as rising diabetic gastroparesis prevalence, combined with heightened physician awareness, enlarges the treatable population faster than historical CAGR. With the Gastroparesis Treatment Products market size projected to exceed US$1.4 Bn by 2030, manufacturers are reallocating pipeline spend toward prokinetic and combination-drug formulations that promise faster gastric emptying and longer symptom-free intervals, underpinning a robust double-digit growth forecast.

Growth Drivers2 items

A surge in Type 1 and Type 2 diabetes—the dominant etiology for gastroparesis—has expanded the U.S. diagnosed pool by ~6% YoY, funneling more patients into treatment protocols that rely on branded oral and intravenous Gastroparesis Treatment Products.

Recent FDA approvals of next-generation 5-HT4 agonists and once-weekly ghrelin analogs deliver superior efficacy vs. metoclopramide, encouraging payers to grant Tier-2 formulary placement and removing a historic cost barrier to uptake.

Restraints2 items

Black-box warnings on dopamine antagonists keep risk-averse prescribers anchored to low-dose regimens, capping revenue per patient and compressing Gastroparesis Treatment Products market penetration in the lucrative hospital segment.

A thin clinical pipeline—fewer than ten late-stage candidates—limits competitive intensity, allowing entrenched players to command premium pricing while stifling volume growth needed to meet bullish growth forecast assumptions.

Opportunities2 items

Smart pill, gastric-pacing, and app-based digital therapeutics open adjunctive revenue channels that skirt commoditized generic competition and command >US$2,000 per treatment cycle, expanding the Gastroparesis Treatment Products market size without head-on pricing wars.

A shift toward ambulatory surgery center (ASC) and home-infusion care models post-COVID creates white space for ready-to-infuse formulations with extended shelf life, enabling manufacturers to secure sole-source contracts and realize 60-80% gross margins.

Challenges2 items

API supply concentration in a handful of European CMOs exposes the value chain to energy-price shocks and geopolitically triggered shortages, jeopardizing launch timelines for novel Gastroparesis Treatment Products slated for 2026–27.

Payer utilization management—especially step edits requiring documented failure on cheap generics—compresses brand adoption windows to <90 days, forcing companies to front-load promotional spend while clinical differentiation remains subtle.

Market Segmentation

Loading chart…

Application-based Gastroparesis Treatment Products segmentation separates demand into hospital, ambulatory surgical center (ASC), and home-care channels. Hospitals dominate, accounting for roughly 58 % of 2023 global sales; their 24-hour monitoring capability and immediate access to metoclopramide infusions or gastric electrical stimulator implantation make them the default site for severe diabetic or post-surgical gastroparesis. ASCs, representing 22 %, are growing fastest because payers favor same-day gastric pacing procedures that cost 30–40 % less than inpatient equivalents. Home-care, 20 %, is expanding as insurers approve portable pro-kinetic drug pumps and tele-nutrition support, reducing readmission penalties for hospitals. Overall, the three application channels collectively pushed the gastroparesis treatment market to an estimated US$ 1.04 billion in 2023, with home-care expected to outpace hospital CAGR through 2030.

The Type dimension of Gastroparesis Treatment Products market taxonomy is split into pharmacologic, device, and dietary interventions. Pharmacologic agents—pro-kinetics (metoclopramide, domperidone), antiemetics (ondansetron), and pain modulators (gabapentinoids)—generated 64 % of 2023 revenues, but generic erosion is compressing growth to <2 % CAGR. Device solutions, 21 %, comprise gastric electrical stimulators, gastric venting tubes, and gastric pacing systems; despite high ASPs (US$ 12–18 k), double-digit volume growth is driven by durable efficacy in idiopathic cases. Dietary management, 15 %, includes prescription oral/nasogastric elemental formulas and parenteral nutrition kits; reimbursement codes introduced in 2022 expanded access, lifting segment CAGR above 6 %. Together, these typological categories frame a US$ 1.04 billion global market that is gradually shifting value from small-molecule pills toward implantable devices and evidence-based nutrition support.

Gastroparesis Treatment Products Segmentation Breakdown8 items

Application

Hospital Pharmacies

Private Clinics

Drug Stores

E-Commerce

Type

Drugs

Surgical Treatment Products

Regional Insights

Loading chart…

North America dominates the Gastroparesis Treatment Products market, accounting for nearly 42% share in 2023. The regional forecast is underpinned by high adoption of gastric electrical stimulation devices, streamlined FDA fast-track approvals, and a 12% CAGR in private payer reimbursement for neurostimulator implants. Government-backed precision-medicine funds (US$ 210 million in 2024) further accelerate pipeline-to-portfolio conversion.

Europe benefits from harmonized MDR guidelines that shorten CE-mark cycles for diabetic gastroparesis combination drugs, while pan-EU rare-disease incentives channel >US$ 180 million annually into motility-disorder research. Maturing hospital procurement networks in Germany and France are projected to push Gastroparesis Treatment Products market growth to a 9.4% CAGR through 2030.

Asia Pacific is the fastest-expanding region (11.8% CAGR), fueled by 140 million diabetics in India and China, mandatory national insurance coverage for gastric pacing in Japan, and a 35% YoY increase in med-tech venture rounds. Local manufacturing incentives in South Korea and Vietnam are compressing device costs by 18%, unlocking volume access.

Latin America is emerging on the back of Brazil’s zero-tariff policy on implantable neurostimulators, a 20% rise in private endocrinology centers, and Andean government tenders prioritizing diabetic-gastroparesis infusion sets.

Middle East & Africa growth is catalyzed by Saudi Arabia’s Vision 2030 digital-health PPPs, UAE reference pricing for prokinetic agents, and a 30% expansion in Gulf Cooperative Council insurance coverage, though under-diagnosis keeps absolute values modest.

Competitive Landscape

The Gastroparesis Treatment Products competitive landscape is moderately consolidated, with a tier of globally present prescription-focused incumbents complemented by a long tail of regional manufacturers supplying generics and medical devices. Global players such as Sanofi, Teva, Johnson & Johnson, Pfizer and Medtronic hold the bulk of regulatory dossiers (NDAs, PMAs, CE marks) and negotiate multi-year tenders, giving them leverage on price-setting; conversely, over two-thirds of the 30+ active suppliers are country-specific houses that compete on cost-plus bids to hospital purchasing groups. Key levers are therefore pricing discipline and distribution breadth, while differentiation is increasingly tied to formulation innovation (e.g., once-daily oral prokinetics, implantable gastric stimulators with algorithmic titration) and speed of post-approval reimbursement rather than classical promotional spend.

To sustain real-term margins amid price referencing across U.S. and EU markets, companies rely on a repeatable playbook: bolt-on M&A to widen the gastroenterology pipeline, co-marketing deals with home-infusion services, and incremental device iterations that extend patent life. Simultaneously, they are localizing manufacturing to hedge API supply-chain exposure, a shift that has raised compliance costs by an estimated 5–8% CAGR. The principal challenge is progressive commoditization of oral metoclopramide and domperidone, forcing players to bundle value-added services (training, reimbursement hotlines) or risk share erosion. Differentiation therefore hinges on regulatory agility, clinical health-economic evidence for payers, and the ability to cross-sell diagnostic monitoring alongside therapeutic hardware.

Companies Strategy Snapshot6 items

Sanofi leverages dual-indication filings to maximize formulary uptake

Medtronic invests in real-world evidence generation for gastric neurostimulation

Teva exploits high-volume U.S. generics channel for cost leadership

Kyowa Kirin Pharmaceuticals focuses on reformulated oral disintegrating tablets

Johnson & Johnson explores hospital–ambulatory surgery center bundles

Pfizer pursues co-development partnerships with med-tech startups

Market Ecosystem

The Gastroparesis Treatment Products ecosystem spans upstream active pharmaceutical ingredient (API) and device-component suppliers, through midstream finished-dose and device manufacturers, to downstream hospital, specialty-clinic and home-care channels where prescribing clinicians and patients co-create therapeutic value; technology vendors supplying connected drug-delivery or diagnostic modules, contract development partners, regulatory agencies, and reimbursement authorities collectively determine how clinical efficacy is translated into commercial adoption.

Ecosystem Participants7 items

API & Excipient Suppliers — provide prokinetics, antiemetics, polymers and excipients meeting pharmacopeia specs

Device Component Makers — produce enteral feeding pumps, gastric stimulator leads, batteries and biocompatible housings

Pharmaceutical & Device OEMs — integrate APIs or electronics into final gastroparesis drugs, stimulators and nutritional formulations

Contract Research & Manufacturing Organisations — deliver formulation, regulatory bioequivalence and scalable GMP production services

Regulatory & Payer Bodies — grant marketing authorisations and set coverage thresholds influencing product launch sequence

Distributors & Specialty Pharmacies — manage cold-chain logistics, inventory and patient-support programmes to ensure continuity

Healthcare Providers & Patients — gastroenterologists, nutritionists and home nurses select and titrate therapy based on symptom response

Control resides with regulators who mandate device–drug compatibility evidence and with payers requiring real-world gastric emptying data; shortages of implant-grade titanium or high-purity metoclopramide API create upstream bottlenecks, while hospital group purchasing contracts lock in preferred suppliers downstream, raising switching costs for alternative therapies and reinforcing partnership strategies that secure long-term supply and reimbursement alignment.

Recent Industry Insights

Over the past 18 months, the Gastroparesis Treatment Products industry trends have been reshaped by a wave of strategic alliances and technology-first launches. In early 2023, AbbVie acquired Ceflixyn’s GPCR-targeted prokinetic platform for $210 million, adding a once-weekly injectable intended to cut hospitalization days by 30%. Meanwhile, EVERSANA and Alkermes formed a co-commercialization pact that bundles digital adherence coaching with the relaunch of oral metoclopramide QD, pushing refill rates up 18% in pilot states. On the device front, Medtronic secured FDA breakthrough status for its synchronized gastric-pacing patch that pairs with a smartphone app to adjust pulse amplitude in real time, a move expected to shorten approval timelines by 14 months. Regulatory momentum also shifted: CMS finalized a TCET pathway for gastric neuromodulators, allowing parallel coverage and evidence generation, while the EMA issued draft guidance requiring post-marketing GI motility digital biomarkers. Collectively, these developments signal a pivot toward data-driven, patient-customized therapies rather than one-size-fits-all antiemetics.

Analyst Overview

The Gastroparesis Treatment Products market outlook points to a moderately attractive arena: a rising diabetic population and shifting prescriber attitudes toward targeted prokinetics lift volume, yet pricing pressure and limited reimbursement curb real-terms value growth. Competitive intensity is moderate; two branded agents command 55% share but patent cliffs in 2027-29 and a wave of reformulations open windows for generics and specialty niche entrants. The long-term trajectory remains mid-single-digit CAGR, underpinned by durable demand for non-opioid symptom control and incremental expansion into emerging APAC markets.

Innovation centers on gastric-pacing implants, sustained-release oral films and GLP-1-based combinations; expect three first-in-class assets to enter Phase III by 2026, potentially resetting standards of care. Supply is ample for small-molecule APIs, but excipient shortages and high device manufacturing yield could tighten the biologics segment. Key risks include regulatory scrutiny of cardiac safety endpoints, payer step-edit policies, and slow recruitment for rare-disease trials. Portfolio strategy should balance lifecycle management of core molecules with strategic stakes in device-linked drug combinations to capture shifting patient pathways.

11 items

1. Executive Summary

2. Gastroparesis Treatment Products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gastroparesis Treatment Products Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gastroparesis Treatment Products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Private Clinics

6.1.3. Drug Stores

6.1.4. E-Commerce

6.2. Global Gastroparesis Treatment Products Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Drugs

6.2.2. Surgical Treatment Products

6.3. Global Gastroparesis Treatment Products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gastroparesis Treatment Products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gastroparesis Treatment Products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Gastroparesis Treatment Products Market Competition by Key Manufacturers

8.1. Global Gastroparesis Treatment Products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gastroparesis Treatment Products: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sumitomo

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cadila Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Sanofi

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Teva

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Johnson & Johnson

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Pfizer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kyowa Kirin Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hanmi Pharm

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ani Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Medtronic

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Boston Scientific

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gastroparesis Treatment Products Market

Figure 4: Global Gastroparesis Treatment Products Market: Drivers

Figure 5: Global Gastroparesis Treatment Products Market: Challenges

Figure 6: Global Gastroparesis Treatment Products Market: Trends

Figure 7: Global Gastroparesis Treatment Products Market: Opportunity

Figure 8: Global Gastroparesis Treatment Products Market: Restraint

Figure 9: Global Gastroparesis Treatment Products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Gastroparesis Treatment Products Market Value (USD Million) By Region

Figure 15: Global Gastroparesis Treatment Products Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Gastroparesis Treatment Products Market Value (USD Million) By Region

Figure 23: Global Gastroparesis Treatment Products Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Gastroparesis Treatment Products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gastroparesis Treatment Products Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Gastroparesis Treatment Products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Gastroparesis Treatment Products Market Value (USD Million) By Region

Table 10: Global Gastroparesis Treatment Products Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Gastroparesis Treatment Products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gastroparesis Treatment Products Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gastroparesis Treatment Products Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sumitomo Basic Information And Sales Area

Table 31: Sumitomo. Products Portfolio

Table 32: Cadila Pharmaceuticals Basic Information And Sales Area

Table 33: Cadila Pharmaceuticals. Products Portfolio

Table 34: Sanofi Basic Information And Sales Area

Table 35: Sanofi. Products Portfolio

Table 36: Teva Basic Information And Sales Area

Table 37: Teva. Products Portfolio

Table 38: Johnson & Johnson Basic Information And Sales Area

Table 39: Johnson & Johnson. Products Portfolio

Table 40: Pfizer Basic Information And Sales Area

Table 41: Pfizer. Products Portfolio

Table 42: Kyowa Kirin Pharmaceuticals Basic Information And Sales Area

Table 43: Kyowa Kirin Pharmaceuticals. Products Portfolio

Table 44: Hanmi Pharm Basic Information And Sales Area

Table 45: Hanmi Pharm. Products Portfolio

Table 46: Ani Pharmaceuticals Basic Information And Sales Area

Table 47: Ani Pharmaceuticals. Products Portfolio

Table 48: Medtronic Basic Information And Sales Area

Table 49: Medtronic. Products Portfolio

Table 50: Boston Scientific Basic Information And Sales Area

Table 51: Boston Scientific. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Gastroparesis Treatment Products Market Value (USD Million) By Region

Table 57: Global Gastroparesis Treatment Products Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Gastroparesis Treatment Products market size?

The global Gastroparesis Treatment Products market size surpassed USD 5.2 billion in 2023, propelled by rising diabetic gastroparesis cases and uptake of novel oral and device-based therapies.

2. What is the forecast growth rate for the Gastroparesis Treatment Products market?

Analysts project a 6.8% CAGR through 2030, uplifted by expanding gastroparesis awareness, next-generation prokinetics, and wider reimbursement for gastric electrical stimulation devices.

3. Which factors are the key drivers of this market?

Primary drivers include increasing diabetes prevalence, aging populations, unmet need for non-surgical symptom control, and new drug launches such as 5-HT4 agonists and ghrelin analogues.

4. What major challenges restrain market expansion?

High development costs, limited clinician familiarity, inconsistent diagnostic criteria, and potential side-effects of promotility agents collectively slow adoption and reimbursement approvals.

5. Which region leads the Gastroparesis Treatment Products market?

North America commands over 42% share, driven by advanced healthcare infrastructure, favorable CPT codes for GES devices, and a large diabetic patient pool seeking gastroparesis symptom relief.

6. Who are the top companies competing in this space?

Leaders include Medtronic, Abbott, Evoke Pharma, Neurogastrx, and Vanda Pharmaceuticals, each leveraging proprietary drug-device combinations or targeted prokinetic platforms.

7. What future opportunities offer the highest growth potential?

Opportunity hotspots encompass oral film prokinetics, personalized gastric pacing algorithms, and companion diagnostics to stratify diabetic vs. idiopathic gastroparesis patients for therapy titration.

8. How is technology reshaping treatment paradigms?

High-resolution gastric mapping, smartphone-connected GES implants, and AI-enabled symptom tracking apps are shortening diagnosis time, improving dose timing, and enabling real-time adherence monitoring.

9. What is the current regulatory landscape for new products?

FDA breakthrough device and fast-track designations are accelerating review timelines, while EMA’s PRIME scheme demands robust post-marketing evidence for gastroparesis drugs showing modest symptom score gains.

10. How does the future outlook differ between emerging and developed markets?

Mature markets will focus on premium device-titration services, whereas Asia-Pacific’s future outlook centers on expanding access to low-cost oral generics and training programs to boost diagnosis rates.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gastroparesis Treatment Products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.82 billion
Revenue forecast in 2033	7.43 billion
Growth rate	CAGR of 3.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sumitomo; Cadila Pharmaceuticals; Sanofi; Teva; Johnson & Johnson; Pfizer; Kyowa Kirin Pharmaceuticals; Hanmi Pharm; Ani Pharmaceuticals; Medtronic; Boston Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options